[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355927-105":59,"doc-detail-355927-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","repurposing-licensed-viral-vaccines-as-anti-cancer-therapeutics-turning-cold-tumors-hot","Repurposing licensed viral vaccines as anti-cancer therapeutics - Turning cold tumors hot","","Rising cancer incidences worldwide underline the need for effective and globally accessible therapies. Oncolytic viruses (OV) are attractive anti-cancer agents but face regulatory hurdles and high costs that slow clinical implementation. Licensed viral vaccines for cancer therapy offer a promising alternative, drawing on established safety profiles and potential cost benefits. This review summarizes preclinical, case, and clinical evidence and mechanisms, including converting “cold” tumors into “hot” immune microenvironments and synergy with immune checkpoint inhibitors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/repurposing-licensed-viral-vaccines-as-anti-cancer-therapeutics-turning-cold-tumors-hot/355927/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/repurposing-licensed-viral-vaccines-as-anti-cancer-therapeutics-turning-cold-tumors-hot/355927.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are oncolytic viruses (OVs) considered attractive anti-cancer agents?","Question",{"text":112,"@type":113},"OVs can selectively infect and kill tumor cells while stimulating anti-tumor immunity, combining specific oncolysis with immune activation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What challenges limit the global clinical implementation of OVs?",{"text":117,"@type":113},"They face stringent regulatory hurdles and excessive costs, and clinical application can be slowed by lengthy development and high regulatory complexity.",{"name":119,"@type":110,"acceptedAnswer":120},"How do licensed viral vaccines help convert “cold” tumors into “hot” tumors?",{"text":121,"@type":113},"Viral vaccines can transform the tumor immune microenvironment from a suppressive state into an active one, improving immune infiltration and response potential, similar in concept to OVs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355927,1790441292,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","HUMAN VACCINES & IMMUNOTHERAPEUTICS 2026, VOL. 22, NO. 1, 2694180 [https://doi.org/10.1080/21645515.2026.2694180](https://doi.org/10.1080/21645515.2026.2694180)  \nMINI-REVIEW  \nRepurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot  \n[Dorine A. de](Dorine A. de) Bont a\\#, Maud Reugebrink b\\#, Nadine van Montfoort a&, and Vera Kemp b& aDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands; bDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands  \nABSTRACT  \nRising cancer incidences worldwide underline the need for effective and globally accessible therapies. Oncolytic viruses (OV), targeting tumor cells and stimulating anti-tumor immunity, are attractive anti-cancer agents but face challenges like stringent regulatory hurdles and excessive costs, which decelerate their global clinical implementation. Licensed viral vaccines for cancer therapy have emerged as a promising alternative to OVs, leveraging their well-established safety profiles and potential cost benefits. This review discusses the current understanding on their anti-cancer effects. Preclinical experiments, case studies and clinical trials highlight their anti-cancer potential and reveal underlying mechanisms. Similar to OVs, viral vaccines can transform “cold” tumor immune microenvironments into “hot,” synergize with immune checkpoint inhibitors, and are not necessarily hampered by pre-existing immunity. Collectively, they represent a promising and readily available addition to cancer therapy. Further studies into optimizing efficacy, delivery, and synergy, as well as clinical evaluation are warranted to fully realize their anti-cancer potential.  \nGraphical abstract summarizing the mechanism of action induced by licensed vaccines. ICI = immune checkpoint inhibitor.  \nARTICLE HISTORY  \nReceived 2 April 2026 Revised 29 May 2026 Accepted 19 June 2026  \nKEYWORDS  \nViral vaccines; drug repurposing; cancer immunotherapy; oncolytic virotherapy; tumor immune microenvironment  \nIntroduction  \nCancer remains a critical global health challenge, ranking second as the leading cause of death worldwide according to the World Health Organization. 1 The rising incidence of cancer underscores the urgent need for cost-effective and globally accessible therapeutic approaches to improve treatment outcomes.  \nIn recent years, immunotherapy has emerged as a promising strategy in cancer treatment by harnessing the patient’s immune system to target tumor cells.2 Immunotherapy with immune checkpoint inhibitors (ICI) has advanced cancer therapy by showing impressive clinical responses in a number of malignancies including melanoma and lung cancer. However, efficacy can be hampered by a lack of tumor-specific Tcells, low immune cell infiltration, and an immunosuppressive tumor microenvironment.3  \nAmong various immunotherapeutic approaches, oncolytic virus (OV) therapy has shown considerable potential. OVs have the unique capacity to selectively infect and kill cancer cells while simultaneously stimulating the immune system to mount a robust anti-tumor response. This dual mechanism of action – specific oncolysis and immune stimulation – positions OV therapy as a compelling option for treating malignancies. Notably, in 2015, Talimogene laherparepvec (T-VEC) became the first OV approved by the  \nCONTACT Vera Kemp  [v.kemp@lumc.nl](v.kemp@lumc.nl)  Department of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, Leiden 2333 ZC, The Netherlands.  \n\\#Shared first authors.  \n&Shared last authors.  \n© 2026 The Author(s) . Published with license by Taylor & Francis Group, LLC.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ([http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/),)[),](http://creativecommons.org/licenses/by-nc/4.0/),)[ ]","cbCaicrjheW8XD9S","https://ap.wps.com/l/cbCaicrjheW8XD9S","pdf",1393698,12,"English","# Introduction\n## Immunotherapy and immune checkpoint inhibitors\n## Oncolytic virus therapy\n## Repurposing licensed viral vaccines\n# Anticancer effects and mechanisms\n## Converting “cold” to “hot” tumors\n## Synergy with immune checkpoint inhibitors","[{\"question\":\"Why are oncolytic viruses (OVs) considered attractive anti-cancer agents?\",\"answer\":\"OVs can selectively infect and kill tumor cells while stimulating anti-tumor immunity, combining specific oncolysis with immune activation.\"},{\"question\":\"What challenges limit the global clinical implementation of OVs?\",\"answer\":\"They face stringent regulatory hurdles and excessive costs, and clinical application can be slowed by lengthy development and high regulatory complexity.\"},{\"question\":\"How do licensed viral vaccines help convert “cold” tumors into “hot” tumors?\",\"answer\":\"Viral vaccines can transform the tumor immune microenvironment from a suppressive state into an active one, improving immune infiltration and response potential, similar in concept to OVs.\"}]","Repurposing licensed viral vaccines as anti-cancer therapeutics - Turning cold tumors hot | PDF",1790121798,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38202703a9bc258039b8b4b482013144.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0ff7ba1b27f04671f0e2342166fc4f9.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24471cc2dddffb54508209665febdc9b.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d41a8fed55db2ad17c84e7d1e61bcd8.webp",980,1306]